—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Tempus AI, Inc. Class A Common Stock（TEM）— 同業公司組

數據截至2026-10-09 — 評分每個交易日晚間重新計算。分組標準＝首先為共同的Closelook指數成分，其次為產業。Closelook研究日記，不構成投資建議。

Tempus AI, Inc. Class A Common Stock的Closelook綜合評分為39/100，在同業公司組內排名第9位（共9家）——組內評分最高的是Halozyme Therapeutics Inc（74/100）。

名稱綜合動能品質估值訊號距52週高點
TEM Tempus AI, Inc. Class A Common Stock39731815neutral33.6%
HQY HealthEquity Inc61626846info13.9%
VEEV Veeva Systems Inc Class A60957331bull8.3%
HNGE Hinge Health, Inc.56946226ok0.4%
BTSG BrightSpring Health Services, Inc. Common Stock48652440ok13.6%
HALO Halozyme Therapeutics Inc74939451ok5.5%
BION.SW BB Biotech AG73589681info13.8%
DXCM DexCom Inc66818038watch8.8%
LLY Eli Lilly and Company64709129watch9.5%

評分為Closelook全部涵蓋範圍內的相對讀數——方法論詳見公司評分說明。訊號燈來自每日夜間訊號看板。

FAQ · from the current data · as of 2026-10-09

Quick answers

Tempus AI, Inc. Class A Common Stock在Closelook涵蓋範圍內的同業公司有哪些？

分組首先根據共同的Closelook指數成分，其次根據產業：HealthEquity Inc (HQY)、Veeva Systems Inc Class A (VEEV)、Hinge Health, Inc. (HNGE)、BrightSpring Health Services, Inc. Common Stock (BTSG)、Halozyme Therapeutics Inc (HALO)、BB Biotech AG (BION.SW)、DexCom Inc (DXCM)、Eli Lilly and Company (LLY)。

TEM相對同業公司的評分如何？

Tempus AI, Inc. Class A Common Stock的綜合評分為39/100，組內排名第9位（共9家），截至2026-10-09；組內最高綜合評分為Halozyme Therapeutics Inc（74/100）。Closelook評分為研究日記讀數，不構成評等或投資建議。

Related in the Closelooknet universe

then Health Information Services, then Healthcare. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.